OncoMatch/Clinical Trials/NCT06435910
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Is NCT06435910 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies DC vaccines for multiple myeloma or plasmacytoma.
Treatment: DC vaccines — The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Demographics
Prior therapy
Must have received: combination therapies
Very good partial or complete remission (CR) after prior combination therapies.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06435910 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received combination therapies.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages